Arbutus Biopharma Corporation (ABUS) Market Cap & Valuation Ratios
Arbutus Biopharma Corporation (ABUS) has a market cap of $831.0M, a trailing P/E of 5.3 and a price-to-sales ratio of 4.6, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ABUSArbutus Biopharma CorporationFollow ABUS — free
—
Price chart with a free account
- Market cap
- 831.0M
- P/E TTM
- 5.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| ABUS | 0.8 | 5.3 | 4.1 | 5.0 | -3.0% | +1079% | 82% | 83% |
| RIGL | 0.9 | — | 3.0 | 9.4 | 8.8% | +3% | 31% | 17% |
| CRVS | 0.9 | — | — | — | -5.1% | — | — | -42% |
| MGTX | 0.9 | 11.0 | 2.1 | 4.3 | 1.2% | +948% | 46% | 165% |
| ALMS | 0.9 | — | 110.0 | — | — | — | — | -127% |
| AKTS | 0.9 | — | — | — | — | — | — | — |
| SVRA | 0.9 | — | — | — | -12.8% | — | — | -109% |
| ANRO | 0.9 | — | — | — | -8.0% | — | — | — |
| KURA | 0.9 | — | 4.5 | — | -13.7% | +25% | -412% | — |
| FDMT | 0.8 | — | 4.8 | — | — | — | -214% | -56% |
| ARDX | 0.8 | — | 1.6 | — | -2.3% | +17% | -8% | -13% |
| Median of these 10 | 11.0 | 3.8 | 6.8 | -5.1% | +21% | -8% | -42% |
P/E 5.3 vs. a peer median of 11.0; EV/Sales 4.1 vs. 3.8.
Growth vs. price
each dot a company · hover or tap for valuesArbutus Biopharma Corporation — questions
- What is Arbutus Biopharma Corporation's market cap?
- $831.0M.
- What is Arbutus Biopharma Corporation's P/E ratio?
- 5.3 on trailing twelve-month earnings to 2026-06-30.
- What is Arbutus Biopharma Corporation's price-to-sales ratio?
- 4.6.
Every figure on this page comes from Arbutus Biopharma Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.